From: The landscape of bispecific T cell engager in cancer treatment
NCT identifier | Phase | Indications | Number of patients | Drug | Format | Target | Results | Reference |
---|---|---|---|---|---|---|---|---|
NCT03625037 | 1/2 | R/R B-NHL | 67 | Epcoritamab | Fully human IgG1-based bsAb | CD20/CD3 | In DLBCL ≥12 mg (n = 18), ORR: 66.7% (6CRs) In FL ≥ 0.76 mg (n = 8), ORR:100% (2CRs) In MCL (n = 4) ORR: 50% (1 CR, 1 PR) | [65] |
NCT02290951 | 1 | R/R B-NHL | 127 | Odronextamab | Fully human IgG4-based bsAb | CD20/CD3 | In FL ≥ 5 mg (n = 28), ORR: 92.9% (CR rate: 75.0%) In DLBCL without prior CAR T therapy ≥80 mg (n = 10), ORR: 60% (CR rate: 60%) In DLBCL with prior CAR T therapy ≥80 mg (n = 21), ORR: 33.3% (CR rate: 23.8%) | [66] |
NCT02500407 | 1 | R/R FL | 62 | Mosunetuzumab | Fully humanized IgG1-based bsAb | CD20/CD3 | ORR: 68% (CR rate: 50%, PR rate: 18%) | [67] |
NCT02924402 | 1 | R/R NHL and CLL | 44 | XmAb13676 | Fully humanized bsAb | CD20/CD3 | In NHL 80–125 μg/kg (n = 18), ORR: 33.3%. In CLL 20 μg/kg (n = 5): ORR: 25% | [68] |
NCT03075696 | 1 | R/R NHL | 38 | Glofitamab | Fully humanized IgG1-based bsAb with a 2:1 molecular format | CD20/CD3 | ORR:62.5%, CMR rate: 40.6% In aNHL (n = 24), ORR: 50.0%, CMR rate: 29.2%. In iNHL (n = 8), ORR: 100.0%, CMR rate: 75.0% | [69] |
NCT04082936 | 1 | R/R NHL | 14 | IGM-2323 | Fully humanized IgM-based bsAb | CD20/CD3 | Tumor size reduction rate: 64% (2 PRs) | [70] |
NCT02520427 | 1 | R/R AML | 55 | AMG 330 | Two tandem scFvs | CD33/CD3 | ORR: 19% (CR rate: 7%, CRi rate: 10%) | [52] |
NCT03224819 | 1 | R/R AML | 30 | AMG 673 | Two tandem scFvs with Fc region | CD33/CD3 | Decrease in blasts in bome marrow rate: 44% | [53] |
NCT02514239 | 1 | R/R MM | 42 | AMG 420 | Two tandem scFvs | BCMA/CD3 | ORR: 31% At dose of 400 mg/d (n = 10), ORR: 70% (5 MRD-negative CRs, 1 PR, and 1 VGPR) | [58] |
NCT03287908 | 1 | R/R MM | 75 | AMG 701 | Two tandem scFvs with Fc region | BCMA/CD3 | At the dose of 3–12 mg (n = 45), ORR: 36%; At the dose of the 9 mg (n = 6), ORR: 83% (3PRs, 2VGPRs) | [59] |
NCT03145181 | 1 | R/R MM | 128 | Teclistamab | Fully humanized IgG1-based bsAb | BCMA/CD3 | At the dose of 1500 μg/kg sc (n = 22), ORR: 73% (≥ CR rate: 23% and ≥ VGPR rate: 55%) | [71] |
NCT03761108 | 1 | R/R MM | 49 | REGN5458 | Fully humanized IgG1-based bsAb | BCMA/CD3 | At the dose of 96 mg ORR: 63% (≥ VGPR rate: 95%) | [61] |
NCT03269136 | 1 | R/R MM | 30 | PF-06863135 | Fully humanized IgG1-based bsAb | BCMA/CD3 | At the dose of 215 to 1000 μg/kg SC (n = 20), ORR: 80% (6CRs, 3 VGPRs,6 PRs) | [72] |
NCT03933735 | 1 | R/R MM | 38 | TNB-383B | Fully humanized IgG1-based bsAb | BCMA/CD3 | At the dose of ≥40 mg, ORR: 80% (VGPR rate: 75%) | [64] |
NCT03275103 | 1 | R/R MM | 51 | Cevostamab | Fully humanized IgG1-based bsAb | FcRH5/CD3 | At the dose of ≥3.6-20 mg (n = 29), ORR: 51.7% (6 CRs, 4 VGPRs, and 5 PRs) | [73] |
NCT03399799 | 1 | R/R MM | 137 | Talquetamab | Fully humanized IgG4-based bsAb | GPRC5D/CD3 | At the dose of 20–180 μg/kg IV (n = 18), ORR: 78% (6/6 responded at the 60 μg/kg) At the dose of 135–405 μg/kg SC (n = 12) ORR: 67% (3/4 responded at the 405 μg/kg) | [74] |
NCT02152956 | 1/2 | PIF and ER AML | 38 | Flotetuzumab | Two inter-exchange of Fv domains | CD123/CD3 | CRR: 42.1% (7 CR, 4 CRh, 4 CRi, and 1 MLFS) In PIF AML (n = 24), CRR: 45.8% (5 CR, 3 CRh, and 3 CRi) In ER AML (n = 14), CRR: 35.7% (2 CR, 1 CRh, 1CRi and 1 MLFS) | [75] |